Why the study?
Trends in systolic blood pressure thresholds for initiating antihypertensive treatment in patients with type 2 diabetes and the impact of age and frailty were not well known.
How have systolic blood pressure thresholds for initiating antihypertensive treatment in patients with type 2 diabetes changed over time, and are they influenced by age or frailty?
How have systolic blood pressure thresholds for initiating antihypertensive treatment in patients with type 2 diabetes changed over time, and are they influenced by age or frailty?
Despite guideline shifts toward personalized care, SBP thresholds for initiating antihypertensives in diabetes decreased uniformly over time without adjusting for age or frailty.
SBP thresholds for antihypertensive initiation in diabetes declined uniformly across frailty; leaves open drivers of temporal trends and guideline adherence.
OBJECTIVE: To assess trends in systolic blood pressure (SBP) thresholds at initiation of antihypertensive treatment in patients with type 2 diabetes and the impact of age and frailty on these trends. STUDY DESIGN AND SETTING: A repeated cross-sectional cohort study (2007-2014) using the Groningen Initiative to Analyse Type 2 diabetes Treatment database was conducted. The influence of calendar year, age or frailty and the interaction between year and age or frailty on SBP thresholds were assessed using multilevel regression analyses adjusted for potential confounders. RESULTS: We included 4819 patients. The mean SBP at treatment initiation was 157 mm Hg in 2007, rising to 158 mm Hg in 2009 and decreasing to 151 mm Hg in 2014. This quadratic trend was significant (p<0.001). Older patients initiated treatment at higher SBP, but similar decreasing trends after 2009 were observed in all age groups. There were no significant differences in SBP thresholds between patients with different frailty groups. The association between year and SBP threshold was not influenced by age or frailty. CONCLUSION: After an initial rise, the observed SBP thresholds decreased over time and were not influenced by age or frailty. This is in contrast with changed guideline recommendations towards more personalised treatment during the study period and illustrates that changing prescribing practice may take considerable time. Patient-specific algorithms and tools focusing on when and when not to initiate treatment could be helpful to support personalised diabetes care.
No takes yet. Share an insight, caveat, or question.
Ambrož et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: